Hsbc Holdings PLC Has $147.94 Million Holdings in Becton, Dickinson and Company (NYSE:BDX)

Hsbc Holdings PLC raised its holdings in Becton, Dickinson and Company (NYSE:BDX) by 2.3% during the 2nd quarter, HoldingsChannel reports. The institutional investor owned 632,659 shares of the medical instruments supplier’s stock after purchasing an additional 14,130 shares during the period. Hsbc Holdings PLC’s holdings in Becton, Dickinson and Company were worth $147,936,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds have also recently bought and sold shares of the business. Vanguard Group Inc. increased its holdings in Becton, Dickinson and Company by 0.8% in the 4th quarter. Vanguard Group Inc. now owns 26,123,450 shares of the medical instruments supplier’s stock valued at $6,369,681,000 after buying an additional 195,931 shares during the period. Massachusetts Financial Services Co. MA increased its holdings in Becton, Dickinson and Company by 1.8% in the 2nd quarter. Massachusetts Financial Services Co. MA now owns 4,905,114 shares of the medical instruments supplier’s stock valued at $1,146,374,000 after buying an additional 87,230 shares during the period. Bank of New York Mellon Corp increased its holdings in Becton, Dickinson and Company by 8.5% in the 2nd quarter. Bank of New York Mellon Corp now owns 4,412,163 shares of the medical instruments supplier’s stock valued at $1,031,167,000 after buying an additional 346,720 shares during the period. Mitsubishi UFJ Asset Management Co. Ltd. increased its holdings in Becton, Dickinson and Company by 4.3% in the 1st quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 2,539,663 shares of the medical instruments supplier’s stock valued at $628,440,000 after buying an additional 105,821 shares during the period. Finally, Longview Partners Guernsey LTD increased its holdings in Becton, Dickinson and Company by 7.9% in the 1st quarter. Longview Partners Guernsey LTD now owns 2,321,435 shares of the medical instruments supplier’s stock valued at $574,439,000 after buying an additional 170,500 shares during the period. Institutional investors own 86.97% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities research analysts have issued reports on BDX shares. Citigroup lowered their price target on shares of Becton, Dickinson and Company from $260.00 to $255.00 and set a “neutral” rating on the stock in a report on Wednesday, July 10th. Evercore ISI dropped their target price on shares of Becton, Dickinson and Company from $290.00 to $285.00 and set an “outperform” rating for the company in a research report on Tuesday, July 2nd. The Goldman Sachs Group started coverage on shares of Becton, Dickinson and Company in a research report on Thursday, May 30th. They set a “buy” rating and a $274.00 target price for the company. Raymond James dropped their target price on shares of Becton, Dickinson and Company from $275.00 to $270.00 and set an “outperform” rating for the company in a research report on Friday, August 2nd. Finally, StockNews.com upgraded shares of Becton, Dickinson and Company from a “hold” rating to a “buy” rating in a research report on Thursday, August 8th. One investment analyst has rated the stock with a hold rating and eight have assigned a buy rating to the stock. According to data from MarketBeat, Becton, Dickinson and Company presently has an average rating of “Moderate Buy” and a consensus target price of $279.50.

Becton, Dickinson and Company Trading Up 0.1 %

BDX opened at $231.58 on Thursday. The company has a current ratio of 1.85, a quick ratio of 1.36 and a debt-to-equity ratio of 0.70. The stock has a market capitalization of $66.93 billion, a PE ratio of 51.01, a PEG ratio of 1.91 and a beta of 0.42. Becton, Dickinson and Company has a 1-year low of $218.75 and a 1-year high of $269.52. The firm has a 50-day moving average price of $235.23 and a two-hundred day moving average price of $235.54.

Becton, Dickinson and Company (NYSE:BDX) last posted its quarterly earnings data on Thursday, August 1st. The medical instruments supplier reported $3.50 earnings per share for the quarter, beating the consensus estimate of $3.31 by $0.19. The firm had revenue of $4.99 billion during the quarter, compared to analysts’ expectations of $5.08 billion. Becton, Dickinson and Company had a net margin of 7.13% and a return on equity of 14.49%. The company’s quarterly revenue was up 2.3% compared to the same quarter last year. During the same quarter last year, the company posted $2.96 EPS. As a group, equities analysts anticipate that Becton, Dickinson and Company will post 13.1 earnings per share for the current fiscal year.

Becton, Dickinson and Company Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Monday, September 30th. Shareholders of record on Monday, September 9th will be given a $0.95 dividend. This represents a $3.80 annualized dividend and a yield of 1.64%. The ex-dividend date is Monday, September 9th. Becton, Dickinson and Company’s payout ratio is presently 83.70%.

About Becton, Dickinson and Company

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.